Recent submissions
Now showing items 2801-2820 of 4716
-
Ubiquitin-mediated regulation of necroptosis
(Institute of Cancer Research (University Of London), 2020-01-31)Regulated cell death is a fundamental cellular process that is critical for the development and survival of multicellular organisms. Cell death and inflammation are essential to restore tissue homeostasis following tissue ... -
A cellular automaton model for spheroid response to radiation and hyperthermia treatments.
(NATURE PORTFOLIO, 2019-11-27)Thermo-radiosensitisation is a promising approach for treatment of radio-resistant tumours such as those containing hypoxic subregions. Response prediction and treatment planning should account for tumour response ... -
Focused Ultrasound-Mediated Hyperthermia in Vitro: An Experimental Arrangement for Treating Cells under Tissue-Mimicking Conditions.
(ELSEVIER SCIENCE INC, 2019-12-01)An experimental arrangement that allows in vitro exposure of cells to focused ultrasound-mediated hyperthermia (43°C-55°C) in a tissue-mimicking phantom with biological, acoustic and thermal properties comparable to those ... -
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
(2019-12)Disease recurrence (locoregional, distant) exerts a significant clinical impact on the survival of estrogen receptor-positive breast cancer patients. Many of these recurrences occur late, more than 5 years after original ... -
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.
(2019-12)Late disease recurrence (more than 5 years after initial diagnosis) represents a clinical challenge in the treatment and management of estrogen receptor-positive breast cancer (BC). An international workshop was convened ... -
Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
(TAYLOR & FRANCIS LTD, 2019-07-03)Introduction: Liposarcomas (LPS) are a heterogeneous group of adipocytic soft tissue sarcomas with limited treatment options in the advanced/metastatic setting. Pazopanib is a multi-target tyrosine kinase inhibitor (TKI) ... -
Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer.
(NATURE PUBLISHING GROUP, 2019-11-15)The major changes in hormone levels that occur through the menstrual cycle have been postulated to affect the expression of hormone-regulated and proliferation-associated genes (PAGs) in premenopausal ER+ breast cancer. ... -
Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial.
(PUBLIC LIBRARY SCIENCE, 2019-11-12)BACKGROUND: Young male cancer survivors have lower testosterone levels, higher fat mass, and worse quality of life (QoL) than age-matched healthy controls. Low testosterone in cancer survivors can be due to orchidectomy ... -
Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT.
(NATURE PUBLISHING GROUP, 2020-06-01)BACKGROUND: The development of prostate cancer can be influenced by genetic and environmental factors. Numerous germline SNPs influence prostate cancer susceptibility. The functional pathways in which these SNPs increase ... -
Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer.
(CELL PRESS, 2019-07-02)Endocrine therapy (ET) is the standard of care for estrogen receptor-positive (ER+) breast cancers. Despite its efficacy, ∼40% of women relapse with ET-resistant (ETR) disease. A global transcription analysis in ETR cells ... -
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
(2020-01)BACKGROUND:Two large clinical trials have shown a reduced rate of breast cancer development in high-risk women in the initial 5 years of follow-up after use of aromatase inhibitors (MAP.3 and International Breast Cancer ... -
Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.
(ELSEVIER SCI LTD, 2016-06-01)BACKGROUND: The hormonal manipulation 5-Fluoro-uracil Epirubicin Cyclophosphamide (HMFEC) trial was developed at a time of uncertainty around the dose intensity of chemotherapy given to premenopausal patients with node ... -
Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses.
(NATURE PUBLISHING GROUP, 2019-08-02)Breast cancer is a highly heterogeneous disease. Although differences between intrinsic breast cancer subtypes have been well studied, heterogeneity within each subtype, especially luminal-A cancers, requires further ... -
Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: Efficacy and Toxicity in the DELINEATE Trial.
(ELSEVIER SCIENCE INC, 2020-03-15)PURPOSE: To report a planned analysis of the efficacy and toxicity of dose escalation to the intraprostatic dominant nodule identified on multiparametric magnetic resonance imaging using standard and hypofractionated ... -
ISBN 978-3-030-11391-9
(Springer, 2019-03-01) -
Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials
(American Society of Hematology, 2019-08-27)<jats:title>Abstract</jats:title><jats:p>Chronic lymphocytic leukemia patients with mutated immunoglobulin heavy-chain genes (IGHV-M), particularly those lacking poor-risk genomic lesions, often respond well to chemoimmunotherapy ... -
Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification.
(MDPI, 2019-11-25)The concept of precision medicine has been around for many years and recent advances in high-throughput sequencing techniques are enabling this to become reality. Within the field of breast cancer, a number of signatures ... -
Evaluating a digital tool for supporting breast cancer patients: a randomized controlled trial protocol (ADAPT).
(BMC, 2020-01-15)BACKGROUND: There are a growing number of mHealth tools for breast cancer patients but a lack of scientific evidence for their effects. Recent studies have shown a mix of positive and negative impacts on users. Here we ... -
Biomarker-guided trials: Challenges in practice.
(ELSEVIER INC, 2019-12-01)Biomarker-guided trials have drawn considerable attention as they promise to lead to improvements in the benefit-risk ratio of treatments and enhanced opportunities for drug development. A variety of such designs have been ...